Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cadonilimab + fruquintinib + paclitaxel-albumin
- Development stage
- Unknown
- Lead developer
- Kangfang Sainuo Pharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Oral
01
Overview
This is a combination regimen consisting of three agents: cadonilimab, fruquintinib, and paclitaxel-albumin. Cadonilimab is a bispecific monoclonal antibody targeting both PD-1 and CTLA-4 immune checkpoints, designed to enhance antitumor immune responses. Fruquintinib is an oral small molecule inhibitor of vascular endothelial growth factor receptors 1, 2, and 3 (VEGFR1/2/3), which blocks angiogenesis in tumors. Paclitaxel-albumin (nab-paclitaxel) is a nanoparticle formulation of the chemotherapy agent paclitaxel bound to human serum albumin; it disrupts microtubule function during cell division, leading to cancer cell death. This combination aims to leverage immunotherapy with antiangiogenic therapy and cytotoxic chemotherapy for synergistic antitumor effects.
- Brand names
- Abraxane (paclitaxel-albumin)
- Other names
- paclitaxel protein-bound particles for injectable suspensionnanoparticle albumin-bound paclitaxelprotein-bound paclitaxel
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)PDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)
Beyond the preview
Go deeper on cadonilimab + fruquintinib + paclitaxel-albumin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cadonilimab + fruquintinib + paclitaxel-albumin.